María Otaola
A5009383674- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis and Related Diseases
- Comparative International Legal Studies
- Legal processes and jurisprudence
- Sarcoidosis and Beryllium Toxicity Research
- Nosocomial Infections in ICU
- Medical Imaging and Pathology Studies
- Ultrasound in Clinical Applications
- Pneumonia and Respiratory Infections
- Ultrasound and Hyperthermia Applications
- Criminal Justice and Penology
- Inhalation and Respiratory Drug Delivery
- Medical Malpractice and Liability Issues
- Comparative constitutional jurisprudence studies
- Atomic and Subatomic Physics Research
- Family and Matrimonial Law
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Occupational and environmental lung diseases
- Eosinophilic Disorders and Syndromes
- Occupational exposure and asthma
- Inflammatory Myopathies and Dermatomyositis
- Pulmonary Hypertension Research and Treatments
- Voice and Speech Disorders
- Rheumatoid Arthritis Research and Therapies
- Latin American socio-political dynamics
Instituto Nacional de Rehabilitación Psicofísica
2019-2024
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
2019-2021
St. Joseph’s Healthcare Hamilton
2020
McMaster University
2020
Hospital Alemán
2017
Universidad Nacional de Córdoba
2012-2016
Hospital Británico de Buenos Aires
2011-2015
Fundación Universitaria San Pablo CEU
2014
University of Buenos Aires
2013
Fundación Universitaria Los Libertadores
2013
Current treatments for idiopathic pulmonary fibrosis slow the rate of lung function decline, but may be associated with adverse events that affect medication adherence. In phase 2 trials, pamrevlumab (a fully human monoclonal antibody binds to and inhibits connective tissue growth factor activity) attenuated progression without substantial events.
Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare, irreversible, and progressive disease of the lungs. Common genetic variants, in addition to nongenetic factors, have been consistently associated with IPF. Rare variants identified by candidate gene, family-based, exome studies also reported associate However, extent which rare genome-wide, may contribute risk IPF remains unknown. Objectives: We used whole-genome sequencing investigate role on risk. Methods: As part Trans-Omics for...
Abstract Background In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced rate of ILD progression adverse events that were manageable for most patients. We investigated potential impact immunomodulatory therapies on efficacy safety nintedanib. Methods Subjects ILDs other than idiopathic pulmonary fibrosis, who had shown within prior 24 months despite management clinical practice, randomized to receive or...
Abstract Background and Objective It is still controversial how to screen for interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). We aimed evaluate the performance of ultrasound (LUS) as a screening tool RA‐ILD compare it chest auscultation, x‐ray pulmonary function tests (PFTs). Methods Cross‐sectional study consecutive RA evaluated at Rheumatology Clinic Buenos Aires between January December 2022. High‐resolution computed tomography (HRCT) was gold standard...
<h3>Background:</h3> Interstitial lung disease (ILD) in rheumatoid arthritis (RA) is an extra-musculoskeletal manifestation with high mortality. Early detection could improve the quality of life these patients. High-resolution chest tomography (HRCT) diagnostic method choice, but radiation limits its use. Different clinical, laboratory, genetic and ultrasonographic parameters have been proposed for this condition. <h3>Objectives:</h3> Identify sociodemographic clinical variables associated...
It is still controversial how to screen for interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). We aimed evaluate the performance of ultrasonography (LUS) as screening tool RA-associated (ILD), and compare it that physical exam, chest X-ray, pulmonary function tests (PFTs). <b>Methods:</b> cross-sectional study consecutive RA evaluated by rheumatology clinic Institute Psychophysical Rehabilitation Buenos Aires (Argentina), from January December 2022. High resolution...
<b>Background:</b> In the INBUILD trial, nintedanib slowed FVC decline in patients with non-IPF progressive fibrosing ILDs. <b>Aim:</b> Assess influence of disease-modifying antirheumatic drugs (DMARDs) and/or glucocorticoids at baseline on effect trial. <b>Methods:</b> The rate and adverse events (AEs) over 52 weeks were assessed by use DMARDs baseline. <b>Results:</b> vs no baseline, mean (SD) was 2288 (700) 2388 (775) mL, age 65.4 (9.8) 66.2 (9.7) years, 53.1% 54.4% male, respectively....
<b>Background:</b> Interstitial lung disease (ILD), is the main cause of mortality in Idiopathic inflammatory myopathy (IIM). Epidemiological, prognostic and treatment information are scarce. The goal was to characterize a cohort IIM patients compare response immunosuppression (IS) among different types IIM. <b>Methods:</b> Observational, multi-centric study 30 centers from Argentina Uruguay. <b>Outcomes:</b> Response IS defined as worsening: decline FVC >10%; improvement: increase...
El presente artículo aborda el fenómeno de la contratación internacional. Tratándose una temática fundamental importancia en intercambio bienes y servicios nuestros días, se analizan las tendencias derecho comparado del mundo globalizado que vivimos. A su vez, situación actual Latinoamérica específicamente Argentina, dada profunda revisión internacional privado ha tenido este país, debido a nueva codificación civil comercial.